On Monday, ProQR Therapeutics N.V (NASDAQ: PRQR) was -5.00% drop from the session before settling in for the closing price of $1.40. A 52-week range for PRQR has been $1.40 – $4.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 82.57%. When this article was written, the company’s average yearly earnings per share was at -24.58%. With a float of $70.76 million, this company’s outstanding shares have now reached $102.71 million.
In terms of profitability, gross margin is 92.57%, operating margin of -162.98%, and the pretax margin is -147.68%.
ProQR Therapeutics N.V (PRQR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward ProQR Therapeutics N.V stocks. The insider ownership of ProQR Therapeutics N.V is 32.74%, while institutional ownership is 42.32%.
ProQR Therapeutics N.V (PRQR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.73% during the next five years compared to 25.70% growth over the previous five years of trading.
ProQR Therapeutics N.V (NASDAQ: PRQR) Trading Performance Indicators
You can see what ProQR Therapeutics N.V (PRQR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of ProQR Therapeutics N.V (PRQR)
Compared to the last year’s volume of 0.46 million, its volume of 0.83 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 8.24%. Additionally, its Average True Range was 0.12.
During the past 100 days, ProQR Therapeutics N.V’s (PRQR) raw stochastic average was set at 1.37%, which indicates a significant decrease from 6.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.51% in the past 14 days, which was lower than the 72.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0556, while its 200-day Moving Average is $2.3572. Nevertheless, the first resistance level for the watch stands at $1.3833 in the near term. At $1.4367, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4833. If the price goes on to break the first support level at $1.2833, it is likely to go to the next support level at $1.2367. Now, if the price goes above the second support level, the third support stands at $1.1833.
ProQR Therapeutics N.V (NASDAQ: PRQR) Key Stats
There are 105,213K outstanding shares of the company, which has a market capitalization of 139.93 million. As of now, sales total 20,460 K while income totals -30,040 K. Its latest quarter income was 4,610 K while its last quarter net income were -9,910 K.
